THE COST OF INTEGRATING WHOLE GENOME SEQUENCING INTO THE CARE OF CARDIOMYOPATHY PATIENTS- SENSITIVITY AND SCENARIO ANALYSES

Author(s)

Christensen KD1, Phillips KA2, Green RC1, Dukhovny D3
1Brigham and Women's Hospital, Boston, MA, USA, 2University of California – San Francisco, San Francisco, CA, USA, 3Oregon Health and Science University, Portland, OR, USA

OBJECTIVES: To estimate the cost of integrating whole genome sequencing (WGS) into the care of cardiology patients, including the implications of different approaches for reporting secondary findings.

METHODS: Cardiology patients with diagnoses of dilated or hyptertrophic cardiomyopathy (n=100) were randomized to review their family histories of disease alone (control arm) or with WGS reports (WGS arm). The incremental cost of family history and WGS analyses was estimated by using a microcosting approach. “Immediately attributable” health care utilization were referrals and tests that were ordered in response to family history and/or WGS information, as reported by cardiologists on checklists completed at the end of each disclosure session. Total health sector costs were estimated over a six-month period by identifying services and out-of-pocket costs in medical records and via patient self-report, and by again applying CMS fee schedules as cost weights. Scenario analyses included comparisons of different reporting strategies, including omission of secondary findings altogether.

RESULTS: WGS identified new cardiomyopathy variants in four patients, including one causal variant and three variants of uncertain significance. Immediately attributable services were identified for only one patient in the control arm and one patient in the WGS arm. Analyses that considered only immediately attributable costs showed a mean cost of $5,270 in the WGS arm and $176 in the control arm (∆=$5,094, 95%CI: -$5,015 to $5,175, p<0.001). Analyses that considered total health sector costs over a six-month period showed a mean cost of $13,376 in the WGS arm and $9,841 in the control arm (∆=$3,535, 95%CI: -$2,490 to $8,970, p=0.24). Scenario analyses showed an average savings of only $72 per patient when secondary findings were omitted altogether.

CONCLUSIONS: WGS increased short-term costs in cardiomyopathy patients, although no impact on downstream costs was observed. Secondary findings had a negligible impact on total costs.

Conference/Value in Health Info

2018-05, ISPOR 2018, Baltimore, MD, USA

Value in Health, Vol. 21, S1 (May 2018)

Code

PCV18

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Cardiovascular Disorders, Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×